Experienced in Spontaneous Coronary Artery Dissection (SCAD)

Yujie X. Zhou

Beijing Key Laboratory Of Precision Medicine Of Coronary Atherosclerotic Disease, 
Beijing, CN 
Experienced in Spontaneous Coronary Artery Dissection (SCAD)
Beijing Key Laboratory Of Precision Medicine Of Coronary Atherosclerotic Disease, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Yujie Zhou practices in Beijing, China. Zhou is rated as an Experienced expert by MediFind in the treatment of Spontaneous Coronary Artery Dissection (SCAD). Their top areas of expertise are Acute Coronary Syndrome, Coronary Heart Disease, Heart Attack, Percutaneous Coronary Intervention (PCI), and Heart Bypass Surgery.

Their clinical research consists of co-authoring 251 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Spontaneous Coronary Artery Dissection (SCAD).

Locations

Beijing Key Laboratory Of Precision Medicine Of Coronary Atherosclerotic Disease, Beijing, China
Other Locations
Tianjin, China
Chengdu, 610065, China
Longxian Chengguanzhen, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

CYP2C19 Genotype-GUided Dual Antiplatelet theRapy in pAtieNts Treated With New Generation Drug Eluting stEnts (the GUARANTEE Study)
CYP2C19 Genotype-GUided Dual Antiplatelet theRapy in pAtieNts Treated With New Generation Drug Eluting stEnts (the GUARANTEE Study)
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2024
Intervention Type: Genetic
Study Phase: Not Applicable
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of AK102 in Patients With Heterozygous Familial Hypercholesterolemia
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of AK102 in Patients With Heterozygous Familial Hypercholesterolemia
Enrollment Status: Completed
Publish Date: March 02, 2023
Intervention Type: Drug
Study Drugs: AK102, Statins, Ezetimibe
Study Phase: Phase 2
View 1 Less Clinical Trial

251 Total Publications

Latent Class Analysis Identifies Distinct Patient Phenotypes Associated With Mistaken Treatment Decisions and Adverse Outcomes in Coronary Artery Disease.
Latent Class Analysis Identifies Distinct Patient Phenotypes Associated With Mistaken Treatment Decisions and Adverse Outcomes in Coronary Artery Disease.
Journal: Angiology
Published: July 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhou's expertise for a condition
ConditionClose
    View All 32 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile